PD04: Prostate Cancer: Basic Research & Pathophysiology II

Podium Session Moderator(s)

• 

  Allen Gao, MD, PhD

  University of California Davis
• SG

  Sergio Guzman, MD
• 

  Ganesh Raj, MD, PHD

  UT Southwestern Medical Center

Presentations:

• 9:30 AM – 9:40 AM CST

  PD04-01: Evaluation of copy number and allelic imbalance of BRCA2 by next-generation sequencing to predict prognosis and drug sensitivity in prostate cancer
  

  Podium Presenter: Makoto Sumitomo
• 9:40 AM – 9:50 AM CST

  PD04-02: Using genomic and transcriptomic properties to determine androgen response in Ductal Prostate Cancers and determine efficacy of Poly(ADP-ribose) polymerase inhibitors with androgen signalling inhibitors therapy in vitro
  

  Podium Presenter: Weranja Kalana Ranasinghe, MD, PhD, MBBS – Monash Health
• 9:50 AM – 10:00 AM CST

  PD04-03: Genetic and Pathway Alterations of Prostate Cancer : From Localized to Metastatic Prostate Cancer
  

  Podium Presenter: Chang Eil Yoon
• 10:00 AM – 10:10 AM CST

  PD04-04: Molecular correlates with PSMA expression in prostate cancer
  

  Podium Presenter: Adam Weiner
• 10:10 AM – 10:20 AM CST

  PD04-05: Towards a New Horizon in Prostate Cancer: PSMA-Targeted Docetaxel-Conjugated Nanomedicines for Intratumoral Treatment in Xenograft Model
  

  Podium Presenter: Adrian Bernal-Gomez
• 10:20 AM – 10:30 AM CST

  PD04-06: Identifying novel regulators of macrophage tumor cell metabolic interactions in prostate cancer
  

  Podium Presenter: Asmaa Elkenawi, PhD
• 10:30 AM – 10:40 AM CST

  PD04-07: The Bivalent Bromodomain Inhibitor; MT-1 Inhibits Prostate Cancer Growth
  

  Podium Presenter: Allison Feibus, MD,MS
• 10:40 AM – 10:50 AM CST

  PD04-08: Balixafortide, a CXCR4 inhibitor, synergizes with docetaxel to diminish tumor growth in a prostate cancer model of bone metastasis.
  

  Podium Presenter: Tyler Joseph Robinson, BS – University of Michigan
• 10:50 AM – 11:00 AM CST

  PD04-09: Combination treatment with HSP70/STUB1 modulator and enzalutamide yields synergistic activity in advanced prostate cancer
  

  Podium Presenter: Chengfei Liu, MD, PHD – University of California, Davis
• 11:00 AM – 11:10 AM CST

  PD04-10: Pre-Clinical Studies to Advance Zilovertamab-Based Anti-ROR1 Dual Specificity CAR T-cell Therapy for Metastatic Prostate Cancer.
  

  Podium Presenter: Christina A. M. Jamieson, PHD – University of California, San Diego
• 11:10 AM – 11:20 AM CST

  PD04-11: MCT inhibition resensitizes enzalutamide-resistant prostate cancer cells to enzalutamide
  

  Podium Presenter: Nagalakshmi Nadiminty
• 11:20 AM – 11:30 AM CST

  PD04-12: Radiotherapeutic Treatment of Prostate Cancer Cells Promotes the Release of Potentially Deleterious and Immunologically Active Extracellular Vesicles
  

  Podium Presenter: Ryan Molony, PhD (he/him/his)